Osteoporosis

Internal Medicine

Cesar Libanati practices Internal Medicine. Cesar Libanati has written publications. He has 22 publications published with PubMed. The lastest paper is: 'Time Course of Bone Mineral Density Changes With Denosumab Compared With Other Drugs in Postmenopausal Osteoporosis: A Dose-response Based Meta-analysis.' He accepts Medicare.

Publications

---

• Time Course of Bone Mineral Density Changes With Denosumab Compared With Other Drugs in Postmenopausal Osteoporosis: A Dose-response Based Meta-analysis.
• Romosozumab in Postmenopausal Women with Low Bone Mineral Density.
• Improvements in hip trabecular, subcortical, and cortical density and mass in postmenopausal women with osteoporosis treated with denosumab.
• Femoral and vertebral strength improvements in postmenopausal women with osteoporosis treated with denosumab.
• Advanced CT based In Vivo Methods for the Assessment of Bone Density, Structure, and Strength.
• Denosumab densitometric changes assessed by quantitative computed tomography at the spine and hip in postmenopausal women with osteoporosis.
• Denosumab significantly increases DXA BMD at both trabecular and cortical sites: results from the FREEDOM study.
• Impact of denosumab on the peripheral skeleton of postmenopausal women with osteoporosis: bone density, mass, and strength of the radius, and wrist fracture.
• Denosumab treatment in postmenopausal women with osteoporosis does not interfere with fracture-healing: results from the FREEDOM trial.
• National Bone Health Alliance Bone Turnover Marker Project: current practices and the need for US harmonization, standardization, and common reference ranges.
• Denosumab reduces the risk of osteoporotic fractures in postmenopausal women, particularly in those with moderate to high fracture risk as assessed with FRAX.
• Five years of denosumab exposure in women with postmenopausal osteoporosis: results from the first two years of the FREEDOM extension.
• Relationship between bone mineral density changes with denosumab treatment and risk reduction for vertebral and nonvertebral fractures.
• Effects of denosumab on bone turnover markers in postmenopausal osteoporosis.
• Denosumab improves density and strength parameters as measured by QCT of the radius in postmenopausal women with low bone mineral density.
• Denosumab for prevention of fractures in postmenopausal women with osteoporosis.
• Quantitative computed tomography (QCT) of the forearm using general purpose spiral whole-body CT scanners: accuracy, precision and comparison with dual-energy X-ray ab...
• Comparison of body composition by bioelectrical impedance and dual-energy x-ray absorptiometry in overweight/obese postmenopausal women.
• Comparison of the effect of denosumab and alendronate on BMD and biochemical markers of bone turnover in postmenopausal women with low bone mass: a randomized, blinded...
• Effects of denosumab on the geometry of the proximal femur in postmenopausal women in comparison with alendronate.
• Acute effects of calcitonin nasal spray on serum C-telopeptide of type 1 collagen (CTx) levels in elderly osteopenic women with increased bone turnover.

Schools

---

• Universidad De Buenos Aires Facultad De Ciencias Medicas

• Loma Linda University Med Center

Doctors Specialties

---

• Geriatric Medicine
• Internal Medicine

Accepted Insurances

---

• Choice Plus POS II
• Blue Card PPO
• Advantage Preferred DirectAccess Plus PPO
• Blue Cross Blue Shield of California PPO
• Access Plus Savenet
• Basic Exclusive PPO for Small Business
• Basic PPO
• Enhanced Exclusive for Small Business HMO
• Local Access Plus HMO
• Cigna HMO
• Great West Healthcare-Cigna PPO
• Open Access Plus
• Commercial Insurance Company
• Blue & Gold HMO
• Community Care Network HMO
• Covered California - Bronze PPO
• Employer Group HMO
• Health Net PPO
• Individual and Family PPO
• Medicare Advantage PFFS
• SmartCare HMO
• WholeCare Network HMO
• Medicare MCR
• Molina Healthcare
• MultiPlan PPO
• PHCS Network PPO
• Heritage Signature
• Principal Life
• Tricare
• Choice Plus POS
• Navigate HMO
• Navigate POS
• Options PPO
• PacifiCare HMO
• United Healthcare

Education

---

• Loma Linda University
• University of Buenos Aires

Hospital

---

• Loma Linda University Medical Center

Drug Facts

---

NPI NUMBER		1962563338
NPPES Provider LastName		LIBANATI
NPPES Provider FirstName		CESAR
NPPES Provider ZIPCode		923542033
NPPES Provider State		CA
Specialty Description		Internal Medicine
Total Claim Count		110.0
Distinct Opioid Count		0.0
Opioid Claim Count		0.0
Percent Opioid Claims		0.0

Helpful Reviews

---

Give Anonymous Review

Medicare Facts

---

National Provider Identifier [NPI]	1962563338
Last Name Of The Provider	LIBANATI
First Name Of The Provider	CESAR
View All

Similar Doctors

---

	Dr. Wessam Labib, MD This Doctor is OpenDoctor Recommended.
	Dr. Marian F. Assal, MD
	Dr. Murli M. Raghavan, MD
	Dr. Debra Craig, MD This Doctor is OpenDoctor Recommended.
	Dr. Russell E. Hoxie Jr., MD This Doctor is OpenDoctor Recommended.
	Dr. Debra L. Stottlemyer, MD
	Dr. Jocelyn E. Gunnarsson, MD
	Dr. Euly Langga-Sharifi, MD This Doctor is OpenDoctor Recommended.
	Dr. Denise Townsend, MD This Doctor is OpenDoctor Recommended.
	Dr. John K. Testerman, MD This Doctor is OpenDoctor Recommended.
	Dr. Diane J. Berriman, MD This Doctor is OpenDoctor Recommended.
	Dr. Janice Fuentes, MD This Doctor is OpenDoctor Recommended.
	Dr. Bina Piya, MD This Doctor is OpenDoctor Recommended.
	Dr. Jillian R. Oft, MD
	Dr. Wubanche Zellalem, DO This Doctor is OpenDoctor Recommended.
	Dr. Aristakes Mnatsakanyan, DO This Doctor is OpenDoctor Recommended.
	Dr. Sammy S. Wong, MD This Doctor is OpenDoctor Recommended.
	Dr. Margaret A. Griffin, MD
	Dr. Daniel Castro, MD This Doctor is OpenDoctor Recommended.
	Dr. Kalpita M. Hatti, MD This Doctor is OpenDoctor Recommended.

---

Doctor Directory | TOS | twitter | FB | Angel | blog